Skip to main content

Funding opportunity for NHS Scotland Health Boards to trial Cancer Innovation Challenge PROMs PREMs innovations

FUNDING CALL BRIEF

NHS Scotland Territorial Health Boards can apply for a grant of up to £30,000 (inc VAT) to cover costs involved in trialling one or both of the Cancer Innovation Challenge’s Phase 2 PROMs PREMs innovations (from My Clinical Outcomes and Px HealthCare) for a period of up to 6 months ending 31 December 2019. We anticipate each applicant Health Board to include an element of in kind contribution to the proposed trial.
 

Summary

The Data Lab, funded by the Scottish Government through the Scottish Funding Council, and in collaboration with DHI Scotland and Stratified Medicine Scotland, will award grants of up to £30,000 (inc VAT) to NHS Scotland Territorial Health Boards to cover costs involved in taking on one or both of the Cancer Innovation Challenge’s Phase 2 PROMs PREMs innovations for a 6 month trial.

These innovations are the final two projects funded in the “New approaches to record and integrate cancer PROMS and PREMs” and have been developed and evaluated in pilot NHS Scotland Territorial Health Boards (NHS Lothian and NHS Ayrshire & Arran).

 

What the funding can and cannot cover

The funding can cover any costs directly incurred by the implementation of one or both of the Cancer Innovation Challenge solutions for a trial period. The trial MUST be in cancer care.  This can include the following costs:

  • Staffing resource:
    • in relation to change management
    • in relation to design work with the company
    • eHealth/IT staffing to implement solution
    • in relation to training
  • Systems integration:
    • In relation to integrating the solutions into existing systems such as TrakCare, Clinical Portal
  • Patient engagement/feedback
    • Patient engagement opportunities
    • Activities to measure patient impact
  • Time from the company:
    • In relation to any design work required to customise to the NHS Scotland Territorial Health Board’s needs

The funding cannot cover:

  • Wider implementation of the solution in the pilot NHS Scotland Territorial Health Board (i.e. NHS Ayrshire & Arran cannot apply for funding for implementing My Clinical Outcomes and NHS Lothian cannot apply for funding for implementing Px HealthCare’s OWise for Scotland)
  • Any costs related to implementation of any solution outwith those funded by the Cancer Innovation Challenge
  • Licence fees to the companies (the companies are aware of this limitation)

 

Who is eligible for this funding?

This funding is only available to NHS Scotland Territorial Health Boards. The Board must evidence engagement with the chosen company solution as part of their submission. We anticipate each applicant Health Board to include an element of in kind contribution to the proposed trial.

NHS Ayrshire & Arran may not apply for wider implementation of My Clinical Outcomes in their Board.

NHS Lothian may not apply for wider implementation of Px HealthCare’s OWise in their Board.  

Health Boards may submit joint applications with NHS Ayrshire & Arran or NHS Lothian (to gain from previous learnings). The conditions for a joint application are:

  • The patients must be in the non - Ayrshire & Arran and Lothian Health Board area
  • The lead application must be the non-  Ayrshire & Arran and Lothian Health Board
     

The Data Lab, funded by the Scottish Funding Council, and in collaboration with DHI Scotland and Stratified Medicine Scotland, reserve the right to adjust the funding available. The total funding available may be subject to change.

 

What are the two solutions?


My Clinical Outcomes

My Clinical Outcomes (MCO) is an established clinical technology platform that automates the collection and analysis of Patient Reported Outcome Measures (PROMs) in routine clinical practice.

MCO Key features:

  • Configurable and cost-effective web-platform for remotely collecting and using PROMs within weeks.
  • Work with clinicians to configure the platform to local requirements - patient cohorts, assessment details, schedule and frequency flexible and set locally.
  • Initial focus may be on measuring symptoms and toxicity during acute treatment, tracking quality of life during follow-up or screening for late-effects. 
  • Following the Cancer Innovation Challenge, MCO is in routine use by the chemotherapy service at NHS Ayrshire and Arran with initial breast cancer pathway design at The Beatson West of Scotland Cancer Centre complete (go-live pending funding).
  • Elsewhere in the UK, MCO is in use at over 70 hospitals in a variety of conditions and care settings, notably working with Macmillan Cancer Support and The Royal College of Radiologists at an initial three NHS cancer centres to enhance the long-term follow-up of radiotherapy patients (see project video and feedback here).

Further information about My Clinical Outcomes can be found at the bottom of the page in the expandable section


OWise for Scotland (from Px HealthCare)

Px HealthCare (Px) has developed OWise, the UK’s leading, patient-centric mobile app platform improving patient experience, hospital efficiency and oncology outcomes in real-time.

Fully in line with the Scottish government strategy “Beating Cancer: Ambition and Action” (2016) and the country’s focus on practising Realistic Medicine, OWise has already been shown to improve the patient–physician relationship (Young-Afat et al. 2016, JMIR Cancer 2016;2(1):e8). Currently available for breast cancer patients, it will become available for other tumour sites later in 2019.

OWise is a mobile app and website, which:

  • Enables people living with breast cancer to better informed and have access to a range of personalised self-management and support tools
  • Empowers patients to track, review and share their daily, remotely-monitored PRO-data with clinicians who can directly access this from within TrakCare©
  • Is aligned with UKONS to give patients real-time, smart alerts nudging them to seek appropriate medical support when their side effects exacerbate.

View short video about OWise

Further information about Px HealthCare and OWise can be found at the bottom of the page in the expandable section

 

Dates and Deadlines

The call opens at 12 NOON on Monday 1 April 2019.

APPLICATION DEADLINE - The call will close at noon on Wednesday 1 May 2019. You must submit your full application by 12 noon (BST) on 1 May 2019. Late applications will not be accepted.

 

Further Information

Please expand the sections below for further information.

If you have any further questions, please contact Steph Wright, CIC Programme Manager on steph.wright [at] thedatalab.com (subject: NHS%20Scotland%20Health%20Board%20Funding%20Opportunity%20Enquiry)

1. Funding Scope

This funding has been made available to help NHS Scotland Territorial Health Boards on-board innovative solutions funded by the Cancer Innovation Challenge (CIC) for a trial period.

The CIC funded five projects for a feasibility study stage in its competition to find “New approaches to record and integrate cancer PROMS and PREMs”. Two progressed to a final development and evaluation phase - My Clinical Outcomes and OWise for Scotland (from Px HealthCare). Both solutions have had very successful Phase 2 with their pilot Health Boards (My Clinical Outcomes – NHS Ayrshire & Arran, Px HealthCare’s OWise for Scotland – NHS Lothian) and the CIC are keen to support the wider adoption of these innovations across Scotland.

Limited resources can act as a barrier to the adoption of new innovations in the NHS – whether it is staffing to manage the change, or the staffing and IT resources required to undertake the design work to customise and integrate the solution or resource to carry out the training required.

The CIC are therefore offering NHS Scotland Territorial Health Boards an opportunity to receive funding to cover some of these costs and take on the CIC solutions for a trial period in order for the Board to see the solutions in action and gather evidence to support (or not) the use of such a tool in routine cancer care at minimal cost.

NB We cannot fund wider implementation of the solution in the pilot NHS Scotland Territorial Health Board (i.e. NHS Ayrshire & Arran cannot apply for funding for implementing My Clinical Outcomes and NHS Lothian cannot apply for funding for implementing Px HealthCare’s OWise for Scotland)

2. About the Cancer Innovation Challenge

Launched by the Chief Medical Officer for Scotland, Catherine Calderwood, on 24 March 2017, the Cancer Innovation Challenge is a £1M project funded by the Scottish Government through the Scottish Funding Council (SFC) to encourage Innovation Centres in Scotland to work in partnership to help Scotland become a world leading carer for people with cancer.

The project brings together three Innovation Centres, led by The Data Lab in collaboration with the Digital Health and Care Institute (DHI) and Stratified Medicine Scotland (SMS).

The Cancer Innovation Challenge is also supported by NHS NSS, Innovative Healthcare Delivery Programme (IHDP), University of Edinburgh, Health and Social Care Alliance Scotland (the ALLIANCE), Usher Institute and the University of Stirling.

The Challenge has two major work streams:

  1. An open innovation funding call to develop new tools for patient reported outcomes and experiences (PROMs and PREMs) and integrate them into routine cancer care. THIS IS THE WORKSTREAM RELEVANT TO THIS FUNDING OPPORTUNITY (more info below)
  2. An open innovation funding call to identify innovative cancer data science solutions

The Challenge also includes a programme of activities surrounding each work stream involving industry, the public and a variety of stakeholders in the wider health sector. 

Workstream 1. New Approaches to Record and Integrate Cancer PROMs and PREMs Open Funding Call

A two phased open innovation funding call using Innovate UK’s SBRI (Small Business Research Initiative) funding framework.

The goal of this challenge was to create a new approach or mechanism which will enable:

  • Clinicians and the NHS to identify individual patients or groups of patients and obtain their responses to questions at specified time points in their cancer care pathway. Questions may be about their health, their quality of life, their experiences of care, their treatment or associated outcomes.
  • Patients to conveniently respond to questions and provide information to the NHS in a safe, secure, private and trustworthy way.
  • The NHS and clinicians to efficiently and easily collate, analyse and use information reported by patients in a timely way and within the existing NHS infrastructure.

Phase 1 – Five projects awarded for three month feasibility study. Collaborating with NHS Lothian, NHS Ayrshire and Arran, NHS Highlands & Islands and NHS Lanarkshire

Phase 2 – Two Phase 1 projects awarded a further funding to undertake development and evaluation of proof of concept/prototype for 6 months. My Clinical Outcomes (working with haematology and NHS Ayrshire & Arran) and Px HealthCare (working with breast cancer and NHS Lothian).

3. How to Apply

To apply:

Register and apply online. Please note that you once registered, you can submit more than one proposal.

We will not accept late submissions.

Your application is confidential.

The Strategic Management Board of the Cancer Innovation Challenge will assess your proposal and make the final funding decision. Assessment criteria are detailed in the Invitation to Apply

If you need more information, please contact Steph Wright, CIC Programme Manager on steph.wright [at] thedatalab.com (subject: Health%20Board%20Funding%20Opportunity%20query)

4. Reporting

Successful applicants will be required to submit a report to the Cancer Innovation Challenge within one calendar month after the completion of the trial period.

5. Further information about My Clinical Outcomes

My Clinical Outcomes - Digital PROMs in Oncology

PROMs are clinically-validated assessment surveys that quantify the impact of a disease on a patient’s life at a point in time. Tracking PROMs remotely over time allows doctors to make more informed clinical decisions and prioritise clinical capacity to patients that need it most.

The benefits of using PROMs to support routine cancer care are now clear. For example, an RCT published in JAMA in 2017 showed that the approach could extend survivorship of patients with advanced cancer by a median of 5 months.

MCO is currently in use at over 70 UK NHS and private hospitals in a range of conditions and specialties with over 45,000 patients currently registered to over 1,000 clinicians.

Founded and led by a former NHS doctor since 2011, MCO has evolved in-line with the Value-Based Healthcare agenda that shifts the focus of healthcare service delivery to the measurement of outcomes that matter to patients.

MCO has been accredited by the International Consortium of Health Outcomes Measurement (ICHOM) – itself sponsored by the Scottish Government - since 2014 (see listing and reviews), is accredited by the Private Healthcare Information Network to submit outcomes for publication on behalf of UK private hospitals, and is NHS IG Toolkit and ISO27001 compliant for Information Security Management.

During the Cancer Innovation Challenge, MCO worked with the Clinical Director of Cancer Services at NHS Ayrshire and Arran, Dr Peter Maclean, his colleagues and their patients, to configure and deploy the solution to support chemotherapy patients at University Hospital Crosshouse and University Hospital Ayr (see patient and clinician feedback video). MCO is now in use in these hospitals on a rolling two-year service contract. MCO is also now working with clinicians at the Beatson West of Scotland Cancer Hospital to tailor the use of MCO for breast cancer patients.

View video from MCO about their work at NHS Ayrshire & Arran

View video from MCO about their Trigger project with Macmillan and Royal College of Radiologists

Contact tim [at] myclinicaloutcomes.com (subject: CIC%20Health%20Board%20Funding%20Opportunity%20query) (Tim Williams)

and sally.damms [at] myclinicaloutcomes.com (subject: CIC%20Health%20Board%20Funding%20Opportunity%20query) (Sally Damms)

from My Clinical Outcomes for further information

Website: www.myclinicaloutcomes.com

6. Further information about OWise for Scotland from Px HealthCare

OWise for Scotland from Px HealthCare

Established by medical scientists in 2012, Px (which stands for Patient Experience) develops highly effective, patient-centric mobile support tools, including the award-winning app OWise breast cancer, which was launched in the UK in 2016 on the back of its on-going success in the Netherlands.

Selected by the NHS Innovation Accelerator, listed in the NHS Apps Library, and used by NICE as a case study to assess evidence for medical apps (NICE Framework documentation to evaluate digital health technologies), OWise breast cancer is a freely downloadable app and website used widely in the UK and the Netherlands. It gives patients access to personalised self-management tools to support them during treatment as well as easily useable functions to use regularly track and review their wellbeing, side effects and therapy related toxicities.

For the Cancer Innovation Challenge and in collaboration with NHS Lothian, Px has developed an upgraded version of OWise breast cancer (called OWise Closed Loop or CL) which shows actionable insights from real-time Patient Reported Outcome (PRO) data directly in TrakCare©. Also, patients receive personalised alerts nudging them to contact the Cancer Treatment Helpline when their side effects exacerbate (fully aligned with UKONS). A one- year clinical evaluation of OWise-CL, led by Dr. Peter Hall, is underway with results expected to be published late 2019.

In addition to giving patients more control while increasing compliance, OWise delivers:

  • Improved chemotherapy and immunotherapy toxicity management, saving time for charge nurses;
  • Better scheduling of chemotherapy ward;
  • Reduced number of avoidable hospitalisations.

During 2019, OWise will be developed for other tumour sites, with the prostate cancer version currently being developed in collaboration with WoSCAN (as part of the Nesta Healthier Lives Data Fund).

View short video about OWise

Contact anne [at] pxhealthcare.com (subject: CIC%20Health%20Boards%20Funding%20Opportunity%20query) (Anne Bruinvels)

from Px HealthCare for further information.

Website www.owise.uk

Recent Tweets

Cancer Challenge (7 hours ago)
RT @HDR_UK: ANNOUNCEMENT: We are seeking a technology partner to co-develop and deliver the next phase of the Health Data Research Innovat…
Cancer Challenge (Yesterday)
RT @HDR_UK: "Patient representatives are on the leadership team for the project to ensure that patients are involved in the decisions about…

©2018 Cancer Innovation Challenge | Privacy and Cookie Policy | Terms of Use